Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Terminal nucleotidyltransferase 2 (TENT2, also known as GLD2 and PAPD4) is a cytoplasmic, non-canonical poly(A) RNA polymerase that adds adenosine residues to the 3' end of specific mRNAs, forming poly(A) tails. Distinct from canonical nuclear poly(A) polymerases, TENT2 selectively polyadenylates cytoplasmic RNAs and participates in the processing and stabilization of certain microRNAs through monoadenylation. It has established roles in mRNA modification, miRNA metabolism, and RNA surveillance, and mutations have been associated with rare neurological and metabolic diseases. TENT2 is a member of the terminal nucleotidyltransferase (TENT) enzyme family.
Not applicable/no drugs established—TENT2 acts as an enzyme that post-transcriptionally modifies RNA tails, mainly by adenylation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Terminal nucleotidyltransferase 2 (TENT2).